Targeted FVIII expression under the control of its native promoter for hemophilia A gene and cell therapy

被引：0
|
作者：
Zanolini, D. [1 ]
Merlin, S. [1 ]
Fama, R. [1 ]
Borroni, E. [1 ]
Bruscaggin, V. [1 ]
Zucchelli, S. [1 ]
Follenzi, A. [1 ]
机构：
[1] Univ Piemonte Orientale, Vercelli, Italy
来源：
HUMAN GENE THERAPY | 2016年 / 27卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P331
引用
收藏
页码：A147 / A147
页数：1
相关论文
共 50 条
  • [21] Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
    El-Akabawy, Nadia
    Rodriguez, Martin
    Ramamurthy, Ritu
    Rabah, Andrew
    Trevisan, Brady
    Morsi, Alshaimaa
    George, Sunil
    Shields, Jordan
    Meares, Diane
    Farland, Andrew
    Atala, Anthony
    Doering, Christopher B.
    Spencer, H. Trent
    Porada, Christopher D.
    Almeida-Porada, Graca
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2020, 17 : 465 - 477
  • [22] Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
    El-Akabawy, Nadia
    Morsi, Alshaimaa
    George, Sunil
    Shields, Jordan
    Meares, Diane
    Farland, Andrew
    Atala, Anthony
    Doering, Christopher
    Spencer, H. Trent
    Porada, Christopher D.
    Almeida-Porada, Graca
    MOLECULAR THERAPY, 2018, 26 (05) : 358 - 358
  • [23] Immune Tolerance Developed in Platelet-Targeted FVIII Gene Therapy in Hemophilia Mice Is CD4+ T Cell-Mediated
    Chen, Yingyu
    Luo, Xiaofeng
    Chen, Juan
    Schroeder, Jocelyn
    Baumgartner, Christina K.
    Hu, Jianda
    Shi, Qizhen
    BLOOD, 2015, 126 (23)
  • [24] Pharmacodynamic and safety assessment of a FVIII gene therapy construct in hemophilia A mice
    Hoellriegl, W.
    Weiller, M.
    Kopic, A.
    Gritsch, H.
    Gangadharan, B.
    Falkner, F. G.
    Monahan, P. E.
    Rottensteiner, H.
    Scheiflinger, F.
    Turecek, M.
    HUMAN GENE THERAPY, 2016, 27 (11) : A153 - A153
  • [25] Transcriptional and post-transcriptional targeting of FVIII expression to overcome immunological responses to gene therapy for Hemophilia A
    Cannizzo, E. Stefania
    Merlin, S.
    Feola, M.
    Zanolini, D.
    Follenzi, A.
    HUMAN GENE THERAPY, 2013, 24 (12) : A50 - A50
  • [26] Transcriptional and post-transcriptional targeting of FVIII expression to overcome immunological responses to gene therapy for Hemophilia A
    Merlin, S.
    Cannizzo, E. S.
    Feola, M.
    Follenzi, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 210 - 210
  • [27] TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL TARGETING OF FVIII EXPRESSION TO OVERCOME IMMUNOLOGICAL RESPONSES TO GENE THERAPY FOR HEMOPHILIA A
    Merlin, S.
    Cannizzo, E. S.
    Bruscaggin, V.
    Feola, M.
    Follenzi, A.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S119 - S120
  • [28] FVIII Expression Driven by Its Native Promoter by Lentiviral Vectors Allowed Sustained Long-Term FVIII Expression Blunting Immune Responses in Hemophilic Mice
    Fama, Rosella
    Borroni, Ester
    Merlin, Simone
    Bruscaggin, Valentina
    Scardellato, Sharon
    Zanolini, Diego
    Zucchelli, Silvia
    Follenzi, Antonia
    MOLECULAR THERAPY, 2018, 26 (05) : 455 - 455
  • [29] Platelet-Targeted Gene Therapy for Hemophilia
    Shi, Qizhen
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2018, 9 : 100 - 108
  • [30] FVIII Expression by its Native Promoter Sustains Long Term Correction Avoiding Immune Response in Hemophilic Mice
    Fama, Rosella
    Merlin, Simone
    Borroni, Ester
    Zanolini, Diego
    Bruscaggin, Valentina
    Scardellato, Sharon
    Zucchelli, Silvia
    Follenzi, Antonia
    MOLECULAR THERAPY, 2019, 27 (04) : 274 - 274
12345